Goldman Reiterates Denial, CDO Exec. Put On Leave

Apr 20 2010 | 6:52pm ET

Goldman Sachs took the unusual step yesterday of opening its first-quarter earnings conference call to the public. But the good news—the Wall Street giant took in $3.46 billion in profit, up 91% from the year earlier period—was all but ignored in favor of the continuing fallout from the Securities and Exchange Commission’s lawsuit against the firm.

The regulator alleges that the firm misled investors about a collateralized debt obligation it structured and marketed for hedge fund Paulson & Co., hiding Paulson’s role in selecting the securities contained in the deal and its intention to short the CDO. But Goldman executives forcefully reiterated their denials of any wrongdoing.

“We would never intentionally mislead anyone, certainly not our clients or counterparties,” general counsel Gregory Palm said. “We certainly had no incentive to design a transaction that was designed to lose money.”

Palm also took aim at the SEC’s contention that Paulson, which was not charged with any wrongdoing, had played a big role in picking the residential mortgage-backed securities that were included in the CDO.

“The portfolio here was not selected by John Paulson,” Palm said. “The portfolio was selected by ACA” Management, a third-party and major investor in the CDO on the long side. Goldman CFO David Viniar offered another side of Goldman’s defense, noting that ACA and the other investors in the CDO were sophisticated enough to know what they were doing.

Still, the Goldman executive responsible for structuring and marketing the CDO, Fabrice Tourre, has been put on indefinite paid leave. Tourre was also named in the SEC’s fraud suit.

Meanwhile, Goldman CEO Lloyd Blankfein has spent some time dealing with internal damage control, leaving to firm-wide voice mails to staff, acknowledging that the situation was “uncomfortable.”

Uncomfortable and potentially expensive: According to Bernstein Research, the lawsuit could wind up costing Goldman more than $700 million over the next few years. Investors lost about $1 billion on the CDO deal.

In Depth

Q&A: Biotech Investing with Crossover Fund RA Capital

Sep 15 2015 | 5:40pm ET

Boston-based RA Capital Management is an intriguing mix of sophisticated life sciences...


Citadel Supports Manhattan Real Estate With Record Deal

Sep 16 2015 | 3:04pm ET

Never count hedge funds out of a big property deal. The Manhattan real estate market...

Guest Contributor

Hedge Fund Marketing To Independent RIA Firms

Sep 30 2015 | 1:56pm ET

In this contributed article, Bruce Frumerman of Frumerman & Nemeth Inc. explains...


Editor's Note

Upcoming Events